- Current report filing (8-K)
01 Abril 2010 - 5:49PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
March 30, 2010
Date of Report
(Date of Earliest Event Reported)
HOSPIRA, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
1-31946
|
|
20-0504497
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
275 N. Field Drive
Lake Forest, Illinois 60045
(Address Of Principal Executive Offices, including Zip Code)
Registrants Telephone Number, Including Area Code:
(224) 212-2000
Not Applicable
(Former Name or
Former Address, If Changed Since Last Report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 1.01
Entry
into a Material Definitive Agreement
On
March 30, 2010, Hospira, Inc., through its wholly-owned subsidiary,
Hospira Healthcare India Private Limited (Hospira), entered into an amendment
to its Business Transfer Agreement, dated December 15, 2009, by and among
Hospira, Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), and Mr. K.
Raghavendra Rao (the Business Transfer Agreement) to acquire from Orchid its
generic injectable finished-dosage form pharmaceuticals business. The amendment
evidenced certain agreements among the parties in connection with the closing of
the transaction. The foregoing summary description of the amendment to the
Business Transfer Agreement does not purport to be complete and is qualified in
its entirety by reference to such amendment, which is attached hereto as
Exhibit 10.1, and is incorporated herein by reference.
A
copy of the press release announcing the completion of the acquisition is
attached as Exhibit 99.l, and is incorporated by reference herein.
Item 9.01
Financial
Statements and Exhibits
Exhibit No.
|
|
Exhibit
|
|
|
|
10.1
|
|
Amendment
No. 1 to the Business Transfer Agreement, dated March 30, 2010, by and
between Orchid Chemicals & Pharmaceuticals Ltd. and Hospira Healthcare
India Private Limited. Confidential treatment is requested for portions of
this exhibit. Omitted portions have been filed separately with the Securities
and Exchange Commission.
|
99.1
|
|
Press
Release, dated March 30, 2010
|
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HOSPIRA,
INC.
|
|
|
|
|
Dated:
April 1, 2010
|
/s/ Brian
J. Smith
|
|
By:
|
Brian
J. Smith
|
|
Its:
|
Senior
Vice President, General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Exhibit
|
|
|
|
10.1
|
|
Amendment
No. 1 to the Business Transfer Agreement, dated March 30, 2010, by and between
Orchid Chemicals & Pharmaceuticals Ltd. and Hospira Healthcare India
Private Limited. Confidential treatment is requested for portions of this
exhibit. Omitted portions have been filed separately with the Securities and
Exchange Commission.
|
99.1
|
|
Press
Release, dated March 30, 2010
|
4
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024